NCT06646263View on ClinicalTrials.gov

Cellular Immune Responses in Triple-negative Breast Cancer - High Throughput Immunogenetic Studies

Enrolling by invitationOBSERVATIONAL
Enrollment

150

Participants

Timeline

Start Date

March 1, 2024

Primary Completion Date

April 30, 2027

Study Completion Date

April 30, 2028

Conditions
Triple Negative Breast Cancer
Trial Locations (1)

57001

Institute of Applied Biosciences, Thessaloniki

All Listed Sponsors
collaborator

Hellenic Cooperative Oncology Group

OTHER

lead

Institute of Applied Biosciences

OTHER